Download presentation
Presentation is loading. Please wait.
1
Immune Checkpoint Inhibitors in Lung Cancer
3
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. Data that we discuss should be considered preliminary until published in a peer-reviewed journal.
4
Currently Approved Checkpoint Inhibitors for Lung Cancer
5
Standard of Care for NSCLC
6
PD-L1 Testing Core Biopsy vs FNA
7
KEYNOTE-189 Efficacy
8
Choosing Between Monotherapy vs Combination Immunotherapy in PD-L1 High Expressers
9
KEYNOTE-042 Efficacy and Safety
10
Was KEYNOTE-042 Practice Changing?
11
TMB Assessment
12
CheckMate 227 Efficacy
13
CheckMate 227 PD-L1 Subgroups and Safety
14
KEYNOTE-407 Efficacy and Safety
15
IMpower131 Efficacy and Safety
16
EGFR-Mutant NSCLC
17
IMpower150 Efficacy
18
Treatment of EGFR-Mutant NSCLC Faculty Discussion
19
PACIFIC Updated Efficacy and Safety
20
ALCHEMIST Immunotherapy Trial
21
Mesothelioma Emerging Therapies
22
Second- and Third-Line Treatment of SCLC
23
IMpower133 Efficacy and Safety
24
Managing SCLC Faculty Recommendations
25
Overview of irAEs
26
Concluding Remarks
27
Abbreviations
28
Abbreviations (cont)
29
Abbreviations (cont)
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.